Search Results - "Thongsawat, S."

Epidemiology and natural course of chronic viral hepatitis B in Asia by Thongsawat, S

Get full text

Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B by Wang, Y., Thongsawat, S., Gane, E. J., Liaw, Y.-F., Jia, J., Hou, J., Chan, H. L. Y., Papatheodoridis, G., Wan, M., Niu, J., Bao, W., Trylesinski, A., Naoumov, N. V.

“…Summary In the phase‐III GLOBE/015 studies, telbivudine demonstrated superior efficacy vs lamivudine during 2‐year treatment in HBeAg‐positive and…”
Get full text

Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment‐naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II) by Zeuzem, S., Flisiak, R., Vierling, J. M., Mazur, W., Thongsawat, S., Gould, M., Hsu, S.‐J., Buggisch, P., Mutimer, D., Nault, B., Merz, M., Griffel, L. H., Tanno, Hugo, Bessone, Fernando, Terg, Ruben, Frider, Bernardo, Bertuzzi, Romina, Zekry, Amany, Weltman, Martin, George, Jacob, Crawford, Darrell, Moreno, Christophe, Reynaert, Hendrik, Lee, Samuel, Ramji, Alnoor, Tam, Edward, Marotta, Paul, Yoshida, Eric, Samuel, Didier, Alric, Laurent, Goeser, Tobias, Zeuzem, Stefan, Berg, Thomas, Rasenack, Jens, Tsang, Owen, Hui, Aric Josun, Makara, Mihaly, Gervain, Judit, Varga, Marta, Horvath, Gabor, Hunyady, Bela, Vincze, Aron, Gaeta, Giovanni Battista, Alberti, Alfredo, Colombo, Massimo, Andreone, Pietro, Picciotto, Antonino, Sacchi, Paolo, Invernizzi, Pietro, Lee, Younjae, Han, Sangyoung, Lim, Youngsuk, Hwang, Seonggyu, Maldonado, Hector, Flisiak, Robert, Jablkowski, Maciej, Prelipcean, Cristina, Musa, Manuela, Manuc, Mircea, Tanasescu, Coman, Dumitrascu, Dan, Nikitin, Igor, Znoyko, Olga, Ferret, Maria Buti, Gomez, Manuel Romero, Diago, Moises, Calleja, Jose Luis, Hsu, Shih‐Jer, Hu, Tsung‐Hui, Peng, Cheng‐Yuan, Chen, Chi‐Yi, Sukeepaisarnjaroen, Wattana, Tanwandee, Tawesak, Komolmit, Piyawat, Agarwal, Kosh, Mutimer, David, Brown, Ashley, McPherson, Stuart, Poulos, John, Rustgi, Vinod, Lyche, Kip, Karnam, Umaprasanna, Person, John, O'Leary, Jacqueline, Lawitz, Eric, Pound, David, Scarsella, Anthony, Thuluvath, Paul, Mailliard, Mark, Shiffman, Mitchell, Jacobson, Ira, Bacon, Bruce, Dimitroff, James, Reindollar, Robert, Godofsky, Eliot, Van, Kinh Nguyen, Dao, Long, Huu, Hoang Bui, Minh, Yen Lam, Thanh, Ly

“…Summary Background Alisporivir (ALV) is an oral, host‐targeting agent with pangenotypic anti‐hepatitis C virus (HCV) activity and a high barrier to resistance…”
Get full text

Pharmacokinetics, safety and antiviral activity of CMX157, a novel prodrug of tenofovir, administered as ascending multiple doses to healthy volunteers and Hepatitis B virus-infected subjects by Tanwandee, T, Chatsiricharoenkul, S, Thongsawat, S, Sukeepaisarnjaroen, W, Tangkijvanich, P, Komolmit, P, Avihingsanon, A, Piratvisuth, T, Sunthi, P, Mahasanprasert, T, Matkovits, T, Conover, M, Cobb, J, Canizares, C, Sullivan-Bolyai, J

Get full text

An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome by Kellow, J, Lee, O Y, Chang, F Y, Thongsawat, S, Mazlam, M Z, Yuen, H, Gwee, K A, Bak, Y T, Jones, J, Wagner, A

“…Background: Tegaserod has been shown to be an effective therapy for the multiple symptoms of irritable bowel syndrome (IBS) in Western populations. However,…”
Get full text

Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy by Kumthip, K., Pantip, C., Chusri, P., Thongsawat, S., O'Brien, A., Nelson, K. E., Maneekarn, N.

“…Several studies have reported correlation between mutations in core and NS5A proteins of hepatitis C virus (HCV) and response to interferon (IFN) therapy. In…”
Get full text

Adding Boceprevir Yields Better Cost-Saving for Chronic Hepatitis C Genotype 1 Treatment in Thailand by Ferrante, S, Elbasha, E.H, Piratvisuth, T, Tanwandee, T, Lerdlitruangsin, S, Thongsawat, S

Get full text

P0612 : Interferon-gamma-inducible protein 10 promoter polymorphism related with end-of-treatment HBsAg levels and had complementary role in prediction of sustained virologic response to peginterferon in HBeAg-negative chronic hepatitis B: Multicenter study by Thanapirom, K, Suksawatamnuay, S, Sukeepaisarnjareon, W, Tanwandee, T, Thongsawat, S, Leerapun, A, Piratvisuth, T, Boonsirichan, R, Bunchorntavakul, C, Pattanasirigool, C, Pornthisarn, B, Tantipanichtheerakul, S, Sripariwuth, E, Jeamsripong, W, Sanpajit, T, Poovorawan, Y, Komolmit, P

Get full text

Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin by Foster, G. R., Zeuzem, S., Pianko, S., Sarin, S. K., Piratvisuth, T., Shah, S., Andreone, P., Sood, A., Chuang, W.-L., Lee, C.-M., George, J., Gould, M., Flisiak, R., Jacobson, I. M., Komolmit, P., Thongsawat, S., Tanwandee, T., Rasenack, J., Sola, R., Messina, I., Yin, Y., Cammarata, S., Feutren, G., Brown, K. K.

“…Summary Rare interstitial lung disease cases have been reported with albinterferon alfa‐2b (albIFN) and pegylated interferon alfa‐2a (Peg‐IFNα‐2a) in chronic…”
Get full text

Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3 by Pianko, S., Zeuzem, S., Chuang, W.-L., Foster, G. R., Sarin, S. K., Flisiak, R., Lee, C.-M., Andreone, P., Piratvisuth, T., Shah, S., Sood, A., George, J., Gould, M., Komolmit, P., Thongsawat, S., Tanwandee, T., Rasenack, J., Li, Y., Pang, M., Yin, Y., Feutren, G., Jacobson, I. M.

“…Albinterferon alfa‐2b (albIFN) is a fusion protein of recombinant human albumin/recombinant interferon (IFN)‐α‐2b, with ∼200‐h half‐life. Safety/efficacy of…”
Get full text

Tenofovir Versus Placebo to Prevent Perinatal Transmission of Hepatitis B by Jourdain, G, Ngo-Giang-Huong, N, Harrison, L, Decker, L, Khamduang, W, Tierney, C, Salvadori, N, Cressey, T.R, Sirirungsi, W, Achalapong, J, Yuthavisuthi, P, Kanjanavikai, P, Ayudhaya, O.P Na, Siriwachirachai, T, Prommas, S, Sabsanong, P, Limtrakul, A, Varadisai, S, Putiyanun, C, Suriyachai, P, Liampongsabuddhi, P, Sangsawang, S, Matanasarawut, W, Buranabanjasatean, S, Puernngooluerm, P, Bowonwatanuwong, C, Puthanakit, T, Klinbuayaem, V, Thongsawat, S, Thanprasertsuk, S, Siberry, G.K, Watts, D.H, Chakhtoura, N, Murphy, T.V, Nelson, N.P, Chung, R.T, Pol, S, Chotivanich, N

“…(N Engl J Med 2018;378:911–923)Despite vaccination and administration of hepatitis B immune globulin at birth, mother-to-child transmission of hepatitis B…”
Get full text

424 RESPIRATORY ALTERATIONS IN GENOTYPE 2/3 CHRONIC HEPATITIS C PATIENTS TREATED WITH PEGYLATED INTERFERON OR ALBINTERFERON-ALFA-2B PLUS RIBAVIRIN IN A RANDOMIZED STUDY by Foster, G, Flisiak, R, Chuang, W.-L, George, J, Rasenack, J, Sood, A, Komolmit, P, Thongsawat, S, Tanwandee, T, Sola, R, Sukeepaisarnjaroen, W, Weltman, M, Yin, Y, Feutren, G, Brown, K

Get full text

7 TREATMENT OF DECOMPENSATED HBV-CIRRHOSIS: RESULTS FROM 2-YEARS RANDOMIZED TRIAL WITH TELBIVUDINE OR LAMIVUDINE by Gane, E.J, Chan, H.L, Choudhuri, G, Suh, D.J, Chutaputti, A, Safadi, R, Tanwandee, T, Thongsawat, S, Assy, N, Sarin, S.K, Bao, W, Trylesinski, A, Avila, C

Get full text

P1051 EVALUATION OF ESTIMATED GLOMERULAR FILTRATION RATE DURING CONTINUOUS 4-YEAR TREATMENT WITH TELBIVUDINE IN PATIENTS WITH BRIDGING FIBROSIS/CIRRHOSIS by Gane, E.J, Lai, C.-L, Xie, Q, Liaw, Y.-F, Thongsawat, S, Chan, H.L.-Y, Wang, Y, Hwang, S.-G, Safadi, R, Jung, M, Uddin, A, Janssens, N, Trylesinski, A

Get full text

Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B by Jourdain, Gonzague, Ngo-Giang-Huong, Nicole, Harrison, Linda, Decker, Luc, Khamduang, Woottichai, Tierney, Camlin, Salvadori, Nicolas, Cressey, Tim R, Sirirungsi, Wasna, Achalapong, Jullapong, Yuthavisuthi, Prapap, Kanjanavikai, Prateep, Na Ayudhaya, Orada P, Siriwachirachai, Thitiporn, Prommas, Sinart, Sabsanong, Prapan, Limtrakul, Aram, Varadisai, Supang, Putiyanun, Chaiwat, Suriyachai, Pornnapa, Liampongsabuddhi, Prateung, Sangsawang, Suraphan, Matanasarawut, Wanmanee, Buranabanjasatean, Sudanee, Puernngooluerm, Pichit, Bowonwatanuwong, Chureeratana, Puthanakit, Thanyawee, Klinbuayaem, Virat, Thongsawat, Satawat, Thanprasertsuk, Sombat, Siberry, George K, Watts, Diane H, Chakhtoura, Nahida, Murphy, Trudy V, Nelson, Noele P, Chung, Raymond T, Pol, Stanislas, Chotivanich, Nantasak

“…Preventing mother-to-child transmission of hepatitis B virus is an opportunity to prevent lifelong infection and associated complications. This randomized,…”
Get full text

Prolonged Ambulatory Duodeno-Jejunal Manometry in Humans: Normal Values and Gender Effect by Soffer, E E, Thongsawat, S, Ellerbroek, S

“…The aim of this study was to provide a detailed comparison of motor activity in the duodenum and jejunum and between men and women studied by prolonged…”
Get full text

1012 TELBIVUDINE-INDUCED HBEAG SEROCONVERSION IN CHRONIC HEPATITIS B (CHB) IS DURABLE DURING 2 YEARS OFF-TREATMENT FOLLOW-UP by Liaw, Y.-F, Wursthorn, K, Thongsawat, S, Zhou, X.-Q, Hwang, S.G, Chutaputti, A, Teo, E.K, Gane, E.J, Jung, M, Wedemeyer, H, Avila, C

Get full text

Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B by Lau, George K.K, Piratvisuth, Teerha, Luo, Kang Xian, Marcellin, Patrick, Thongsawat, Satawat, Cooksley, Graham, Gane, Edward, Fried, Michael W, Chow, Wan Cheng, Paik, Seung Woon, Chang, Wen Yu, Berg, Thomas, Flisiak, Robert, McCloud, Philip, Pluck, Nigel

“…After 48 weeks of treatment and 24 weeks of follow-up, patients treated with peginterferon either alone or in combination with lamivudine were more likely to…”
Get full text

Effect of acute hyperglycemia on jejunal compliance and peristaltic reflex in healthy humans by SOFFER, E. E, THONGSAWAT, S, HOOGWERF, B. J, SHAH, A

“…Acute hyperglycemia has been shown to affect gastric motor function and colonic peristaltic reflex, but little is known about its effects on the small bowel…”
Get full text

Safety and efficacy of ravidasvir plus sofosbuvir 12 weeks in noncirrhotic and 24 weeks in cirrhotic patients with hepatitis C virus genotypes 1, 2, 3 and 6: The STORM-C-1 phase II/III trial by Andrieux-Meyer, I., Tan, S.-S., Salvadori, N., Simon, F., Cressey, T.R., Said, H.R.H.M., Hassan, M.R.A., Omar, H., Tee, H.P., Chan, W.-K., Goh, K.L., Omar, S.F.S., Kamarulzaman, A., Kumar, S., Thongsawat, S., Thetket, K., Avihingsanon, A., Khemnark, S., Thanprasertsuk, S., Piedagne, J.-M., Brenner, J., Siva, S., Asimah, N., Da Silva, N., Pecoul, B., Lallemant, M., Murad, S.

Get full text